Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 3

KERYX BIOPHARMACEUTICALS INC Form 3 August 03, 2015 FORM 3 UNITED STATES SECUE Was

VI3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

Filing(Check Applicable Line) _X_ Form filed by One Reporting

Form filed by More than One

Person

Reporting Person

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Holmes Scott A			2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol KERYX BIOPHARMACEUTICALS INC [KERX]				
(Last)	(First)	(Middle)	07/27/2015	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)			
C/O KERYX BIOPHARMACEUTICALS,				(Check all applicable)				
INC., 750 AVENUE) LEXING	I'ON		Director 10% Owner X Officer Other				
(Street)				(give title below) (specify below) Chief Financial Officer	6. Individual or Joint/Group			

NEW YORK, NYÂ 10022

(City)	(State)	(Zip)	Table I - Non-Deriva	tive Securit	ies Beneficially Owned
1.Title of Secur (Instr. 4)	ity		2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Sto	ock (Restrict	ed)	7,500	D	Â
Common Sto	ock (Restrict	ed)	45,000 <u>(1)</u>	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	 2. Date Exercisab Expiration Date (Month/Day/Year) Date Exercisable 		3. Title and A Securities Ur Derivative Se (Instr. 4) Title	nderlying	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (Right to Buy)	07/27/2016(2)	07/27/2025	Common Stock	100,000	\$ 8.09	D	Â

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 3

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Holmes Scott A C/O KERYX BIOPHARMACEUTICALS, INC. 750 LEXINGTON AVENUE NEW YORK, NY 10022		Â	Chief Financial Officer	Â	
Signatures					
/s/ Brian Adams, Attorney-in-Fact 08/03/2015					

<u>**</u>Signature of Reporting Person

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

Date

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The 45,000 shares are restricted common stock, with one-third of the 45,000 shares vesting on July 27, 2016, and the remaining shares vesting in equal quarterly installments through the third anniversary of the start date on July 27, 2018.
- (2) The options vest according to the following schedule: one-third of the 100,000 options vest on July 27, 2016, and the remaining shares vest in equal quarterly installments through the third anniversary of the start date on July 27, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.